Filter Results:
(264)
Show Results For
- All HBS Web
(264)
- News (30)
- Research (197)
- Multimedia (2)
- Faculty Publications (103)
Show Results For
- All HBS Web
(264)
- News (30)
- Research (197)
- Multimedia (2)
- Faculty Publications (103)
- 11 May 2020
- Op-Ed
Immigration Policies Threaten American Competitiveness
It is no secret that immigration has reshaped American innovation. Immigrants are the backbone of America’s most innovative industries, provide a quarter of our patent applications, and are numerous among our science and engineering superstars. Taken from World... View Details
Keywords: by William R. Kerr
- Article
Biosimilars and Follow-On Products in the United States: Adoption, Prices, and Users
By: Ariel Dora Stern, Jacqueline L. Chen, Melissa Ouellet, Mark R. Trusheim, Zeid El-Kilani, Amber Jessup and Ernst R. Berndt
Biologic drugs account for a disproportionate share of the increase in pharmaceutical spending in the U.S. and worldwide. Against this backdrop, many look to the expanding market for biosimilars—follow-on products to biologic drugs—as a vehicle for controlling... View Details
Keywords: Pharmaceuticals; Drug Spending; Drug Pricing; Health Care and Treatment; Spending; Price; Markets; Cost Management; United States
Stern, Ariel Dora, Jacqueline L. Chen, Melissa Ouellet, Mark R. Trusheim, Zeid El-Kilani, Amber Jessup, and Ernst R. Berndt. "Biosimilars and Follow-On Products in the United States: Adoption, Prices, and Users." Health Affairs 40, no. 6 (June 2021): 989–999.
- November 2006
- Case
Competitive Headaches (A): The Analgesic Wars
By: Dennis A. Yao
Addresses the problem of competing with a me-too consumer product. Focuses on Bristol-Meyers' 1975 strategy for introducing a competitor to Tylenol in the analgesic market. View Details
- Web
Winners & Runners-Up | New Venture Competition
Winners & Runners-Up 2024 Winners Play Crop Diagnostix: Dubilier Grand Prize Winner, Student Business Track, 2024 New Venture Competition video Play Video duration: 1:31 2024 New Venture Competition Winner,... View Details
- May 2016
- Case
AbbVie
By: Kevin Schulman, Laura Little, Samyukta Mullangi and Stephen Schleicher
This case focuses on the impact of a novel regulatory pathway, the biosimilars pathway, on the strategy of a major pharmaceutical firm that finds its largest product (60% of revenue) at risk. The case reviews the rationale for the pathway, the emerging biosimilars... View Details
- Web
Sample Student Projects - Institute For Strategy And Competitiveness
HBS ISC Resources Resources Video Courses Data Events & Presentations Frameworks News Publications Courses Sample Student Projects MOC Student Projects on Country & Cluster Competitiveness The competitive... View Details
- Web
Winners & Success Stories | New Venture Competition
Winners & Success Stories The New Venture Competition has been the launching pad for many ventures, and not just from the winning teams. With more than half of Harvard Business School alumni classifying themselves as entrepreneurs at some... View Details
- Web
Executive Education Courses - Institute For Strategy And Competitiveness
care as part of their business model Executives from health care insurance companies, government entities that pay for health care, or other payor organizations Leaders from pharmaceutical companies, medical device companies, or other... View Details
- Web
Strategy for Health Care Delivery - Institute For Strategy And Competitiveness
offered in cooperation with the HBS Institute for Strategy and Competitiveness (ISC). Key Benefits In this program, you will use a value framework—first introduced by HBS professor Michael E. Porter in his book Redefining Health Care—as a... View Details
- Web
Value Measurement for Health Care - Institute For Strategy And Competitiveness
part of their business model Executives from health care insurance companies, government entities that pay for health care, or other payor organizations Leaders from pharmaceutical companies, medical device companies, or other health care... View Details
- June 1998
- Supplement
MBA Integrative Exercise: Competition & Strategy, April 1998 , Video
By: Carin-Isabel Knoop
Daniel Vasella, President of Novartis AG, discusses the situation in Indonesia and his ideas of what Suharto should do in the spring of 1998. Drummond Paris, Regional Pharma Head Asia/Pacific, Novartis AG, discusses the opportunities for Novartis in Indonesia and also... View Details
Knoop, Carin-Isabel. "MBA Integrative Exercise: Competition & Strategy, April 1998 , Video." Harvard Business School Video Supplement 898-504, June 1998.
- January 2017 (Revised October 2018)
- Case
Novartis: A Transformative Deal
By: David Collis and Ashley Hartman
When Joe Jimenez became CEO of Swiss-based Novartis in 2010, replacing longtime CEO Dan Vasella, he assumed control of one of the top pharmaceutical companies in the world. Vasella, an avowed advocate of diversification, had expanded the scope of the company and... View Details
Keywords: Novartis; GlaxoSmithKline; Asset Swap; Acquisitions; Divestiture; Strategy Alignment; Pharmaceuticals; Strategy; Business Strategy; Corporate Strategy; Diversification; Consolidation; Mergers and Acquisitions; Pharmaceutical Industry
Collis, David, and Ashley Hartman. "Novartis: A Transformative Deal." Harvard Business School Case 717-453, January 2017. (Revised October 2018.)
- 01 Mar 2007
- News
Daniel Vasella
portfolio of product lines, setting Novartis apart from its global competitors. Although initially regarded by critics as too inexperienced to lead a multinational pharmaceutical company, Vasella has triumphed. Three years ago he was... View Details
- May 1998
- Background Note
Pharma Giants,The: Ready for the 21st Century?
By: Robert H. Hayes and Perry Fagan
Presents the changing competitive dynamics in the global pharmaceutical industry and possible implications for large drug companies. View Details
Hayes, Robert H., and Perry Fagan. "Pharma Giants,The: Ready for the 21st Century?" Harvard Business School Background Note 698-070, May 1998.
- 15 Sep 2016
- News
Price of pharma innovation: Pro
- Article
What to Know About Locating in a Cluster
By: Willy C. Shih and Sen Chai
As a study of two industry clusters in Denmark shows, factors that can make clusters attractive—easy people movement and knowledge spillovers—can also make it harder for individual companies to retain proprietary knowledge. View Details
Keywords: Clusters; Clustering; Competitiveness; Life Sciences; Telecommunications; Science-based; Research And Development; Industry Clusters; Research; Innovation Strategy; Innovation and Management; Geographic Location; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Denmark
Shih, Willy C., and Sen Chai. "What to Know About Locating in a Cluster." Art. 57117. MIT Sloan Management Review 57, no. 1 (Fall 2015): 104–107.
- October 1993 (Revised February 1995)
- Case
Dendrite International
By: Frank V. Cespedes and Marie Bell
Dendrite International is a $23 million (1992 revenues) supplier of sales automation software to pharmaceuticals companies in Europe, Japan, and the United States. The firm's strategy has depended on being a full-service supplier to multinational firms. Impending... View Details
Keywords: Accounting Audits; Cost vs Benefits; Forecasting and Prediction; Marketing Strategy; Risk and Uncertainty; Sales; Competitive Advantage; Information Technology Industry; Japan; Europe; United States
Cespedes, Frank V., and Marie Bell. "Dendrite International." Harvard Business School Case 594-048, October 1993. (Revised February 1995.)
- September 2002 (Revised August 2014)
- Case
Cardinal Health (A): The Medicine Shoppe Acquisition
By: Regina E. Herzlinger, Miguel Abecasis and Brenda Cheng
Robert Walter, the founder and CEO of Cardinal Health, a pharmaceutical distributor, is contemplating the purchase of Medicine Shoppe, a chain of apothecaries. The purchase might be construed as competition against his own drugstore customers. But one of its many... View Details
Keywords: Mergers and Acquisitions; Business Strategy; Competitive Advantage; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Herzlinger, Regina E., Miguel Abecasis, and Brenda Cheng. "Cardinal Health (A): The Medicine Shoppe Acquisition." Harvard Business School Case 303-043, September 2002. (Revised August 2014.)
- May 2011
- Case
The Morrison Company
By: Steven C. Wheelwright and Paul Meyers
The Morrison Company develops and manufactures radio frequency identification tags (RFID) known as smart labels for the retail and pharmaceutical industries. RFID technology is a fast-growing and increasingly competitive industry. Sales have risen dramatically over the... View Details
Keywords: Quantitative Analysis; Technology; Operations Management; Product Lines; Manufacturing; Capacity Planning; Production Planning; Information Technology; Strategy; Production; Organizational Structure; Infrastructure; Product Development; Information Infrastructure; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Wheelwright, Steven C., and Paul Meyers. "The Morrison Company." Harvard Business School Brief Case 114-564, May 2011.
- August 1990 (Revised January 1992)
- Case
Eli Lilly and Co. (B): Europe
Examines the challenges facing the company in light of the changing economic, regulatory, and competitive environment in the European pharmaceutical industry. Examines the steps taken by the company adapting to this changing situation as part of a total globalization... View Details
Keywords: Change Management; Economics; Global Strategy; Business or Company Management; Growth and Development Strategy; Adaptation; Competition; Pharmaceutical Industry; Europe
Yoshino, Michael Y. "Eli Lilly and Co. (B): Europe." Harvard Business School Case 391-033, August 1990. (Revised January 1992.)